Our disease modifying program Alzstatin focuses on reducing the production of toxic Aβ in the brain. Aβ plays a central role in the pathology of Alzheimer’s disease and starts to accumulate in the brain many years before the first symptoms are recognized.
We have in preclinical tests shown that modulation of gamma-secretase reduces production of the Alzheimer-related Aβ42 by up to 50 percent, without affecting other important cell function. The project is further strengthened by recent external clinical results that we consider validate the amyloid-hypothesis as a therapeutically meaningful target.
Recently, great progress has been made towards blood-based diagnostics, which has the potential to enable a cost-effective screening and identification of people at high risk for developing Alzheimer’s disease, thereby selecting the right patients for clinical trials and future treatments.
The video below briefly shows how a compound from the Alzstatin program acts in the brain.